Search research articles
Contact Us
Filters
Showing results (321-330 of 325) with videos related to
Page
of 33
Sort By:
You have reached the last page of results.
This site can display upto 325 results.
American Journal of Medical Genetics. Part A
|
October 8, 2020
Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum
Yanick J Crow, Heather Marshall, Gillian I Rice, et al.
The Lancet. Neurology
|
March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
Randall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine
|
June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Stephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial
Randall J Bateman, Yan Li, Eric M McDade, et al.
JAMA Neurology
|
March 24, 2020
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials
Merit Cudkowicz, Marianne K Chase, Christopher S Coffey, et al.
Page
of 33
Search research articles
Search
Showing results (321-330 of 325) with videos related to
Sort By:
Page
of 33
You have reached the last page of results.
This site can display upto 325 results.
American Journal of Medical Genetics. Part A
|
October 8, 2020
Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum
Yanick J Crow, Heather Marshall, Gillian I Rice, et al.
The Lancet. Neurology
|
March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
Randall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine
|
June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Stephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial
Randall J Bateman, Yan Li, Eric M McDade, et al.
JAMA Neurology
|
March 24, 2020
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials
Merit Cudkowicz, Marianne K Chase, Christopher S Coffey, et al.
Page
of 33